DEXOLIGO Trademark

Trademark Overview


On Wednesday, August 2, 2023, a trademark application was filed for DEXOLIGO with the United States Patent and Trademark Office. The USPTO has given the DEXOLIGO trademark a serial number of 79384444. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, November 6, 2024. This trademark is owned by Dexcel Pharma Technologies Ltd.. The DEXOLIGO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, oligonucleotides, siRNA and antisense RNA for use in the treatment of cancer, hepatitis, neurodegenerative diseases, neurological diseases, hemophilia, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, rare bleeding disorders, iron overload disorders, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, chronic liver infection, anemia, myeloproliferative disorders, auto-immune disorders, chronic kidney diseases, obesity, type 2 diabetes, metabolic syndrome and related conditions, thrombocythemia, gout
dexoligo

General Information


Serial Number79384444
Word MarkDEXOLIGO
Filing DateWednesday, August 2, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateWednesday, November 6, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 26, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, oligonucleotides, siRNA and antisense RNA for use in the treatment of cancer, hepatitis, neurodegenerative diseases, neurological diseases, hemophilia, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, rare bleeding disorders, iron overload disorders, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, chronic liver infection, anemia, myeloproliferative disorders, auto-immune disorders, chronic kidney diseases, obesity, type 2 diabetes, metabolic syndrome and related conditions, thrombocythemia, gout

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 8, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDexcel Pharma Technologies Ltd.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIL

Trademark Events


Event DateEvent Description
Thursday, December 7, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, December 8, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 12, 2023APPLICATION FILING RECEIPT MAILED
Wednesday, April 3, 2024ASSIGNED TO EXAMINER
Monday, April 8, 2024NON-FINAL ACTION WRITTEN
Tuesday, April 9, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, April 24, 2024REFUSAL PROCESSED BY MPU
Wednesday, April 24, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, May 14, 2024REFUSAL PROCESSED BY IB
Tuesday, October 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 31, 2024APPROVED FOR PUB - PRINCIPAL REGISTER